New drug combo aims to improve leukemia treatment in young adults
NCT ID NCT07651176
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which combination leads to the longest time without the cancer returning or getting worse. Participants are randomly assigned to one of three treatment groups and followed for two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lisaftoclax, daunorubicin, cytarabine, homoharringtonine, aclarubicin
- What this could lead to
- If successful, this could identify a more effective chemotherapy combination for young adults with low-risk AML, potentially improving long-term survival without relapse.
- What could go wrong
- This is a mid-stage trial, so results may not confirm superiority. Adding lisaftoclax could increase side effects like bone marrow suppression or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?